RE:RE:RE:RE:RE:RE:Deals are abound!!!!In context of knowing zero about any in place negotiations, I can only comment on my previous & acquired knowledge.
Just after the A.N. Deal & long before our existing
bracelet( Pfizer) , CAR-t , end newest GREAT panc cancer results out of Goblet ( ROche), it was discussed " they" would only consider a number starting with a B...aka $ billion .
Move that forward to today.
The Onc investor presentation clearly talks about, license/ partnerships, but not a total buyout.
Why?
mangement feels the perpetual income stream from licensing would provide longer term value above & beyond a takeover.
Saying that, everyone & every business has a price.
They did comment at on- set of Aware-1, then Irene( Incyte), " they were positioning everything possible to create a competitive environment to gain best opportunities possible , for oncolyicts biotech."
That , imho has been accomplished.
Dollar value of buyout?
More than one billion......top end?
I have no idea.
considering MBc alone is expected to bring $5billion/ year in sales. ( RBC analysts).
mutiple uses?
The upside is massive & contrary to what some believe, has zero to do with existing share price.
everything to do with present value of future sales/ profits, for the acquiring company.
That calculation is always open to interpretation.